NTV Asset Management LLC Buys 7 Shares of Merck & Company, Inc. (MRK)
NTV Asset Management LLC boosted its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 0.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,256 shares of the company’s stock after acquiring an additional 7 shares during the quarter. NTV Asset Management LLC’s holdings in Merck & were worth $1,362,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Merck & by 133.4% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after acquiring an additional 82,454 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Merck & by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after buying an additional 107,201 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in Merck & by 41.9% during the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after buying an additional 87,443 shares during the last quarter. Stevens Capital Management LP acquired a new position in Merck & during the first quarter worth $15,126,000. Finally, Trust Co boosted its stake in Merck & by 2.8% during the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after buying an additional 1,852 shares during the last quarter. Institutional investors own 72.98% of the company’s stock.
Shares of Merck & Company, Inc. (MRK) opened at $54.10 on Tuesday. The stock has a market capitalization of $147,550.00, a PE ratio of 14.19, a P/E/G ratio of 2.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80.
Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business’s revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.07 EPS. research analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current year.
In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.25% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “NTV Asset Management LLC Buys 7 Shares of Merck & Company, Inc. (MRK)” was published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/ntv-asset-management-llc-buys-7-shares-of-merck-company-inc-mrk/1716935.html.
A number of research firms have weighed in on MRK. Sanford C. Bernstein reissued a “buy” rating and set a $64.00 price objective on shares of Merck & in a research note on Wednesday, November 15th. Cowen and Company reissued a “hold” rating and set a $70.00 price objective on shares of Merck & in a research note on Friday, November 3rd. Berenberg Bank reissued a “hold” rating on shares of Merck & in a research note on Wednesday, November 1st. Jefferies Group LLC downgraded Merck & from a “hold” rating to an “underperform” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets set a $68.00 target price on Merck & and gave the company a “buy” rating in a research report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. Merck & currently has a consensus rating of “Hold” and a consensus target price of $66.87.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.